Equities researchers at CL King assumed coverage on shares of Repligen Corporation (NASDAQ:RGEN) in a research note issued on Monday. The brokerage set a “buy” rating and a $41.00 price target on the biotechnology company’s stock. CL King’s target price suggests a potential upside of 26.04% from the stock’s current price.
RGEN has been the subject of several other reports. Zacks Investment Research upgraded shares of Repligen Corporation from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a report on Saturday, August 12th. Stephens reiterated an “overweight” rating and issued a $50.00 price objective on shares of Repligen Corporation in a report on Tuesday, September 26th. BidaskClub cut shares of Repligen Corporation from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Jefferies Group LLC reiterated a “hold” rating and issued a $40.00 price objective on shares of Repligen Corporation in a report on Thursday, October 19th. Finally, First Analysis upgraded shares of Repligen Corporation from an “equal weight” rating to an “overweight” rating and set a $47.00 price objective for the company in a report on Monday, October 2nd. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $44.67.
Repligen Corporation (NASDAQ RGEN) opened at $32.53 on Monday. Repligen Corporation has a 1 year low of $28.48 and a 1 year high of $46.81. The company has a market cap of $1,400.00, a PE ratio of 59.87, a price-to-earnings-growth ratio of 2.31 and a beta of 1.05.
Repligen Corporation (NASDAQ:RGEN) last posted its earnings results on Thursday, November 9th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.11 by $0.04. Repligen Corporation had a net margin of 16.93% and a return on equity of 7.57%. The firm had revenue of $36.58 million during the quarter, compared to analysts’ expectations of $35.69 million. During the same quarter in the prior year, the firm earned $0.08 EPS. Repligen Corporation’s quarterly revenue was up 48.2% on a year-over-year basis. sell-side analysts forecast that Repligen Corporation will post 0.6 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This article was first reported by Transcript Daily and is owned by of Transcript Daily. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://transcriptdaily.com/2017/11/15/repligen-corporation-rgen-coverage-initiated-at-cl-king.html.
Hedge funds have recently added to or reduced their stakes in the stock. Eaton Vance Management acquired a new stake in Repligen Corporation during the second quarter valued at approximately $529,000. Benin Management CORP acquired a new stake in Repligen Corporation during the second quarter valued at approximately $207,000. Jennison Associates LLC acquired a new stake in Repligen Corporation during the second quarter valued at approximately $291,000. Legal & General Group Plc lifted its stake in Repligen Corporation by 15.3% during the second quarter. Legal & General Group Plc now owns 68,677 shares of the biotechnology company’s stock valued at $2,845,000 after purchasing an additional 9,121 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its stake in Repligen Corporation by 162.8% during the second quarter. PNC Financial Services Group Inc. now owns 5,635 shares of the biotechnology company’s stock valued at $234,000 after purchasing an additional 3,491 shares during the last quarter. 96.47% of the stock is owned by institutional investors and hedge funds.
Repligen Corporation Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.